Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019067543) COMPOSITIONS AND METHODS FOR TREATING CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/067543 International Application No.: PCT/US2018/052858
Publication Date: 04.04.2019 International Filing Date: 26.09.2018
IPC:
C07D 239/94 (2006.01) ,C07D 317/48 (2006.01) ,C07D 319/18 (2006.01) ,C07D 321/08 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/55 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
70
condensed with carbocyclic rings or ring systems
72
Quinazolines; Hydrogenated quinazolines
86
with hetero atoms directly attached in position 4
94
Nitrogen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
317
Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
08
having the hetero atoms in positions 1 and 3
44
ortho- or peri-condensed with carbocyclic rings or ring systems
46
condensed with one six-membered ring
48
Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
319
Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
10
1,4-Dioxanes; Hydrogenated 1,4-dioxanes
14
condensed with carbocyclic rings or ring systems
16
condensed with one six-membered ring
18
Ethylenedioxybenzenes, not substituted on the hetero ring
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
321
Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/-C07D319/174
02
Seven-membered rings
04
not condensed with other rings
08
1, 4-Dioxepines; Hydrogenated 1,4-dioxepines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor Oakland, CA 94607-5200, US
Inventors:
NATHANSON, David, A.; US
MAI, Wilson, X.; US
JUNG, Michael, E.; US
CLARK, Peter, M.; US
CLOUGHESY, Timothy, F.; US
KIM, Gyudong; KR
TSANG, Jonathan; US
URNER, Lorenz; US
Agent:
HALSTEAD, David, P.; US
AKHIEZER, Alexander; US
ABELLEIRA, Susan, M.; US
BLOUNT, Jennifer, V.; US
BROW, William, E.; US
Priority Data:
62/563,37326.09.2017US
62/589,97222.11.2017US
Title (EN) COMPOSITIONS AND METHODS FOR TREATING CANCER
(FR) COMPOSITIONS ET MÉTHODES DE TRAITEMENT DU CANCER
Abstract:
(EN) The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present dislcsoure also provides methods oadministering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.
(FR) La présente invention concerne des composés qui sont capables de pénétrer la barrière hémato-encéphalique pour moduler l'activité de la tyrosine kinase EGFR. La présente invention concerne en outre des procédés permettant de traiter le glioblastome et d'autres cancers faisant intervenir EGFR. La présente invention concerne en outre des procédés de traitement du glioblastome et d'autres cancers faisant intervenir EGFR dont on a déterminé qu'ils présentent un métabolisme du glucose modifié en présence d'inhibiteurs. La présente invention concerne également des procédés d'administration à un sujet d'un inhibiteur du métabolisme du glucose et d'un stabilisateur de p53 cytoplasmique.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)